Qi Pan
Boehringer Ingelheim
8 Papers
11 Citations
Qi Pan is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: B-cell activating factor & Polynucleotide. The author has an hindex of 2, co-authored 7 publications.
Chat about Author
Papers
Unexpected Potency Differences between B-Cell–Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound
Amy Marie Nicoletti,Cynthia Hess Kenny,Ashraf Khalil,Qi Pan,Kerry L. M. Ralph,Julie Ritchie,Sathyadevi Venkataramani,David Presky,Scott M DeWire,Brodeur Scott +9 more
TL;DR: An in vitro cell-based analysis of BAFF revealed differences in inhibitory potencies against the various BAFF forms, in particular that belimumab does not potently inhibit BAFF 60-mer and that BAFF trimer activates the human TACI receptor.
20
Patent
Novel anti-baff antibodies
Brodeur Scott,Keith Canada,Pankaj Gupta,Amy Marie Nicoletti,Qi Pan,Sanjaya Singh,Michael Dziegelewski,Philip Nicholas Gorman,Ashraf Khalil,John Miglietta,David Presky,Tao Wu,Haiguang Xiao +12 more
- 30 Jan 2015
TL;DR: In this paper, the present invention relates to anti-BAFF antibody molecules, including novel humanized anti-baFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
10
Patent
Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
Sanjaya Singh,Qi Pan,Rachel Rebecca Barrett,Johnson Leslie S,Pankaj Gupta,Sarah Low,Haixia Wu +6 more
- 21 Jul 2016
TL;DR: In this paper, the disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof, and nucleic acids, cells, and method of production related to the compounds and compositions.
1
Patent
Composé ciblant le facteur d'activation d'il-23 et des lymphocytes b (baff) et utilisations associées
Sanjaya Singh,Qi Pan,Rachel Rebecca Barrett,Johnson Leslie S,Pankaj Gupta,Sarah Low,Haixia Wu +6 more
- 21 Jul 2016
TL;DR: In this paper, the authors present an invention concerne des composes specifiques d'IL-23A and de BAFF, des compositions comprenant les composes, and des methodes d'utilisation associees.
Patent
Anti-baff antibody molecule, pharmaceutical composition comprising this molecule, methods of using same and isolated polynucleotide encoding same
Brodeur Scott,Keith Canada,Pankaj Gupta,Amy Marie Nicoletti,Qi Pan,Sanjaya Singh,Michael Dziegelewski,Philip Nicholas Gorman,Ashraf Khalil,John Miglietta,David Presky,Tao Wu,Haiguang Xiao +12 more
- 08 Nov 2019
TL;DR: In this paper, the authors describe anti-BAFF antibody molecules, including novel humanized anti-BB antibodies, pharmaceutical compositions comprising these molecules and therapeutic methods using the same, particularly a method for treating a subject having a BAFF-associated disorder; a method to treating an inflammatory disease, an autoimmune disease, a respiratory disease, metabolic disorder or cancer, and a method that inhibiting the binding of BAFF to one or more BAFF receptors on a mammalian cell.